IRB #

IRB00009464

Title

A Phase II Study of Sorafenib with Chemotherapy, Radiation, and Surgery for High-Risk Soft Tissue Sarcomas

Principal Investigator

Christopher Ryan

Study Purpose

The purpose of this study is to determine the effects, good and/or bad of the study drug, sorafenib, in combination with chemotherapy and radiation.

Medical Condition(s)

Soft Tissue Sarcoma

Eligibility Criteria

Subjects must be 15 years of age or older.
Subjects must have a diagnosis of soft tissue sarcoma of their extremity or body wall.
Have not had prior anti-cancer treatment.
Subject's medical history will be reviewed in detail for study eligibility.
Other eligibility criteria will apply

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

Approximately 5 years.

Minors Included

No

Contact

Clinical Trials Information Line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

Bayer HealthCare Pharmaceuticals, Inc.

Recruitment End

05/29/2021

Compensation Provided

No


Go Back